Compare Eli Lilly And Co (LLY) vs Workday Inc (WDAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Workday Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Workday Inc trades at $186.59 (market cap $45.26B). The key difference: Eli Lilly And Co is far larger — about 23× Workday Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while Workday Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Workday Inc for 38 Days on average.
| LLY | WDAY | |
|---|---|---|
Market Cap | $1.04T | $45.26B |
Volume | 3,064,878 | 2,342,190 |
Sector | Health | Technology |
52-Week High | $1.28K | $245.67 |
52-Week Low | $799.57 | $112.55 |
Typical Hold Time | 93 Days | 38 Days |
Enterprise Value | $1.09T | $45.63B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Workday (WDAY) trades at $187.81, up 1.93% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.75 exceeding the $2.61 forecast. Revenue growth is robust, projected to reach $10.2B in 2026, and the company maintains a high gross profit margin of 75.8%. Recent strategic moves include expansion into the UAE and AI product launches, though layoffs signal operational realignment.
The outlook for WDAY is positive, driven by AI integration and solid financials, but risks include competitive pressures and execution challenges. Analyst consensus is a Buy with a $202.92 price target, suggesting upside potential. Investors should weigh strong profitability against valuation multiples that remain elevated compared to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Workday Inc
Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →
